Isomorphic Labs raises $5 billion to accelerate drug discovery

Alphabet’s AI-driven drug discovery subsidiary has raised $5 billion. Isomorphic Labs aims to fund its IsoDDE platform and advance its programs toward clinical trials.

Isomorphic Labs, the AI-driven drug discovery company founded by Demis Hassabis, has raised $5 billion, according to CNBC and an article published on November 17, 2026. This massive funding confirms investors’ appetite for tools capable of accelerating the development of new treatments. It comes as the startup has yet to have any approved drugs.

Une pluie de capitaux sur la pharmacie assistée par IA

The funding round was led by Greenoaks and Sequoia Capital, with Andreessen Horowitz as a new entrant, while Alphabet and all existing investors also participated. According to the cited source, Isomorphic Labs had already raised $2.1 billion in May 2026. In six months, the company has thus completed two mega-rounds, clearly indicating where market confidence lies.

The funds are intended to advance IsoDDE, the Isomorphic Drug Design Engine, the company’s internal drug design platform. The company presents it as a system going beyond AlphaFold 3, aiming to better predict molecule binding and docking sites. The vocabulary is technical in this field, but the idea is simple: reduce time wasted testing compounds blindly that will not work.

De DeepMind à la clinique, sans raccourci garanti

Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but currently has no treatments approved by authorities. This is where the story becomes interesting for the market: AI promises in healthcare attract spectacular amounts, but the ultimate proof remains clinical. Algorithms can help select candidates faster, but they do not yet grant marketing authorization themselves.

Demis Hassabis, who founded Isomorphic Labs and stepped back from daily management of Google DeepMind in August 2026, now holds the position of chief scientist at Alphabet. He also received the 2024 Nobel Prize in Chemistry with John Jumper for their work on AlphaFold. This pedigree explains part of the investors’ enthusiasm, even though the path to an approved drug remains long. Biology does not always align with fundraising timing.

Pourquoi cette levée compte pour le secteur

Beyond the amount, this operation shows that AI-assisted pharmacy is moving from a research topic to an industrial competition field. Major laboratories, venture capital funds, and digital giants see it as a lever to shorten R&D cycles and better target molecules. The fundamental question remains: how long will it take before a platform like IsoDDE turns the trial into a marketed treatment?

Key points

  • $5 billion raised, according to CNBC, in November 2026.
  • Greenoaks and Sequoia Capital co-led the round.
  • Alphabet, Novartis, Eli Lilly, and Johnson & Johnson are involved in the project.
  • Isomorphic Labs has no approved drugs yet.

By the numbers

  • $5 billion — amount raised by Isomorphic Labs, November 2026.
  • $2.1 billion — previous round announced in May 2026.
  • 2021 — year the company was founded.
  • 2024 — Nobel Prize in Chemistry awarded to Demis Hassabis and John Jumper.

To read